Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Agarwal N, et al. Among authors: boucher km. Clin Genitourin Cancer. 2014 Apr;12(2):130-7. doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28. Clin Genitourin Cancer. 2014. PMID: 24220220 Free PMC article.
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N. Gill D, et al. Among authors: boucher k. Clin Genitourin Cancer. 2017 Aug;15(4):e599-e602. doi: 10.1016/j.clgc.2016.12.008. Epub 2017 Jan 5. Clin Genitourin Cancer. 2017. PMID: 28131750 Free PMC article.
Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.
Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N. Poole A, et al. Among authors: boucher k. Clin Genitourin Cancer. 2017 Sep 6:S1558-7673(17)30272-0. doi: 10.1016/j.clgc.2017.08.017. Online ahead of print. Clin Genitourin Cancer. 2017. PMID: 28958675
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.
Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N. Maughan BL, et al. Among authors: boucher k. Oncologist. 2018 Dec;23(12):1413-e151. doi: 10.1634/theoncologist.2018-0652. Epub 2018 Nov 1. Oncologist. 2018. PMID: 30575560 Free PMC article. Clinical Trial.
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL. Agarwal N, et al. Among authors: boucher k. Clin Cancer Res. 2020 May 1;26(9):2104-2110. doi: 10.1158/1078-0432.CCR-19-2591. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937614 Free PMC article. Clinical Trial.
Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C. Tward JD, et al. Among authors: boucher k. Clin Genitourin Cancer. 2020 Aug;18(4):274-283.e5. doi: 10.1016/j.clgc.2019.11.023. Epub 2020 Mar 19. Clin Genitourin Cancer. 2020. PMID: 32335059
265 results